230 related articles for article (PubMed ID: 10204806)
1. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites.
Manning AP; Mes-Masson AM; Seymour RJ; Tetrault M; Provencher DM; Tonin PN
Mol Carcinog; 1999 Mar; 24(3):218-25. PubMed ID: 10204806
[TBL] [Abstract][Full Text] [Related]
2. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines.
Benoît MH; Hudson TJ; Maire G; Squire JA; Arcand SL; Provencher D; Mes-Masson AM; Tonin PN
Int J Oncol; 2007 Jan; 30(1):5-17. PubMed ID: 17143508
[TBL] [Abstract][Full Text] [Related]
3. Expression of abnormal transcripts of the FHIT (fragile histidine triad) gene in ovarian carcinoma.
Mandai M; Konishi I; Kuroda H; Nanbu K; Matsushita K; Yura Y; Hamid AA; Mori T
Eur J Cancer; 1998 Apr; 34(5):745-9. PubMed ID: 9713284
[TBL] [Abstract][Full Text] [Related]
4. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
5. Mapping of chromosome 3p deletions in human epithelial ovarian tumors.
Lounis H; Mes-Masson AM; Dion F; Bradley WE; Seymour RJ; Provencher D; Tonin PN
Oncogene; 1998 Nov; 17(18):2359-65. PubMed ID: 9811467
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of FHIT gene alterations in ovarian cancer.
Buttitta F; Marchetti A; Radi O; Bertacca G; Pellegrini S; Gadducci A; Genazzani AR; Bevilacqua G
Br J Cancer; 1998 Apr; 77(7):1048-51. PubMed ID: 9569038
[TBL] [Abstract][Full Text] [Related]
7. FHIT gene abnormalities in both benign and malignant thyroid tumours.
Zou M; Shi Y; Farid NR; al-Sedairy ST; Paterson MC
Eur J Cancer; 1999 Mar; 35(3):467-72. PubMed ID: 10448301
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
9. Expression of aberrant functional and nonfunctional transcripts of the FHIT gene in Burkitt's lymphomas.
Ferrer M; López-Borges S; Lazo PA
Mol Carcinog; 1999 May; 25(1):55-63. PubMed ID: 10331745
[TBL] [Abstract][Full Text] [Related]
10. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
11. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines.
Hendricks DT; Taylor R; Reed M; Birrer MJ
Cancer Res; 1997 Jun; 57(11):2112-5. PubMed ID: 9187105
[TBL] [Abstract][Full Text] [Related]
12. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
13. Impaired FHIT expression characterizes serous ovarian carcinoma.
Ozaki K; Enomoto T; Yoshino K; Fujita M; Buzard GS; Kawano K; Yamasaki M; Murata Y
Br J Cancer; 2001 Jul; 85(2):247-54. PubMed ID: 11461085
[TBL] [Abstract][Full Text] [Related]
14. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
15. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
16. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines.
Mao L; Fan YH; Lotan R; Hong WK
Cancer Res; 1996 Nov; 56(22):5128-31. PubMed ID: 8912845
[TBL] [Abstract][Full Text] [Related]
17. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.
Baffa R; Gomella LG; Vecchione A; Bassi P; Mimori K; Sedor J; Calviello CM; Gardiman M; Minimo C; Strup SE; McCue PA; Kovatich AJ; Pagano F; Huebner K; Croce CM
Am J Pathol; 2000 Feb; 156(2):419-24. PubMed ID: 10666370
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Kholodnyuk ID; Szeles A; Yang Y; Klein G; Imreh S
Cancer Res; 2000 Dec; 60(24):7119-25. PubMed ID: 11156420
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
20. FHIT (fragile histidine triad) gene analysis in cervical intraepithelial neoplasia.
Liu FS; Hsieh YT; Chen JT; Ho ES; Hung MJ; Lin AJ
Gynecol Oncol; 2001 Aug; 82(2):283-90. PubMed ID: 11531281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
